Cynthia Lyle Kelly

Cynthia Lyle Kelly currently serves as Vice President and Global Program Lead for Cardiovascular at Cardurion Pharmaceuticals since November 2024. Prior to this role, Cynthia held the position of Senior Director of Program Leadership at Turnstone Biologics from 2022 to October 2024, and Senior Director, Early Development Program Lead, Cardiovascular at Bristol Myers Squibb from 2020 to 2022. At MyoKardia from 2017 to 2020, Cynthia was the Project Team Leader for the therapeutic development of danicamtiv (MYK-491), where leadership encompassed strategic direction and oversight of a cross-functional team. Additionally, Cynthia was a founding member of the MyoKardia Women's Forum Steering Committee. Earlier roles include Clinical Operations Program Lead for danicamtiv at MyoKardia, Clinical Trial Manager at Medivation, Senior Clinical Research Associate at Quintiles, Clinical Research Coordinator at the University of California, and Undergraduate Intern at Sandia National Laboratories. Cynthia earned a PhD in Cancer Biology from the University of California, San Francisco, and a BS in Cellular and Molecular Biology from Tulane University.